



Kiniksa to Present Riloncept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

August 19, 2019

HAMILTON, Bermuda, Aug. 19, 2019 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](#) (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present final data from an open-label, multicenter Phase 2 clinical trial of riloncept in different pericarditis populations at the American Heart Association (AHA) Scientific Sessions 2019 at the Pennsylvania Convention Center in Philadelphia, PA. Three other research collaborations will be presented to address pericarditis, its burden and its underlying mechanism.

"Recurrent pericarditis is a painful and debilitating condition for patients suffering from repetitive episodes and is an unmet medical need," said Dr. John F. Paolini, MD, PhD, FACC, Chief Medical Officer at Kiniksa. "We look forward to the presentation of multiple sets of data at AHA to help broaden the understanding of disease burden and support riloncept as a potential treatment solution for patients with recurrent pericarditis."

Details of the poster presentations are as follows:

Efficacy and Safety of Riloncept in Recurrent Pericarditis: A Multicenter Phase 2 Clinical Trial

- **Abstract Number:** Sa1094/1094
- **Session:** Experimental and Therapeutic Approaches for Cardiovascular Disease
- **Date and Time:** Saturday, November 16th, 2019 from 4:30 p.m. to 5:00 p.m. Eastern Time
- **Location:** Zone 1, Science and Technology Hall
- **Lead Author:** Allan Klein, Cleveland Clinic

Additional poster presentations of collaborative studies with Dr. David Lin, Minneapolis Heart Institute, and Dr. Antonio Abbate, Virginia Commonwealth University include:

Predictors of Adverse Outcomes in Patients with Acute Pericarditis

- **Abstract Number:** Sa2049/2094
- **Session:** Management of Pericarditis
- **Date and Time:** Saturday, November 16th, 2019 from 1:30 p.m. to 2:00 p.m. Eastern Time
- **Location:** Zone 2, Science and Technology Hall
- **Lead Author:** Alessandra Vecchie, Virginia Commonwealth University

Real-World Clinical Characteristics and Recurrence Burden of Patients Diagnosed with Recurrent Pericarditis in the United States

- **Abstract Number:** Su3090/3090
- **Session:** Epidemiology of Inflammatory, Infiltrative & Iatrogenic Cardiovascular Conditions
- **Date and Time:** Sunday, November 17th, 2019 from 3:00 p.m. to 3:30 p.m. Eastern Time
- **Location:** Zone 3, Science and Technology Hall
- **Lead Author:** David Lin, Minneapolis Heart Institute

Intensification of the Inflammasome Formation in the Pericardium of Patients with Chronic Severe Pericarditis

- **Abstract Number:** Su2332/2332
- **Session:** Concepts on Pericarditis and Myocarditis
- **Date and Time:** Sunday, November 17th, 2019 from 3:00 p.m. to 3:30 p.m. Eastern Time
- **Location:** Zone 2, Science and Technology Hall
- **Lead Author:** Aldo Bonaventura, Virginia Commonwealth University

Kiniksa intends to make the presentations available through the Investors and Media section of its website (www.kiniksa.com) after the AHA embargo lifts, which is expected to be at the time of each presentation.

About Riloncept

Riloncept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 α (IL-1 α) and interleukin 1 β (IL-1 β) signaling. Riloncept was discovered and developed by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the FDA under the brand name

ARCALYST® for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), which includes Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome. IL-1 blockade may interfere with immune response to infections. Serious, life-threatening infections have been reported in patients taking ARCALYST. ARCALYST should be discontinued if a patient develops a serious infection. Taking ARCALYST with TNF inhibitors is not recommended because this may increase the risk of serious infections. Kiniksa exclusively licensed rilonacept from Regeneron for recurrent pericarditis and certain other indications. Rilonacept in recurrent pericarditis is an investigational drug.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.

Every Second Counts!™

Kiniksa Investor and Media Contact

Mark Ragosa

(781) 430-8289

mragosa@kiniksa.com



Source: Kiniksa Pharmaceuticals, Ltd.